This content is a clinical-research news roundup rather than a unified theoretical lecture. Its core underlying principle is diagnostic test evaluation theory: a screening or imaging modality's clinical utility is characterized by its sensitivity for clinically significant disease (formally defined by tumor grade and lesion-size thresholds), and post-hoc stratification of missed cases by severity can reveal whether false negatives are clinically inconsequential, which in turn supports risk-adjusted diagnostic pathways (e.g., biomarker-density thresholds) to reduce unnecessary invasive procedures. Related principles include pharmacokinetic drug-drug interaction theory (mechanism-based interactions altering drug absorption or clearance and affecting treatment efficacy/safety), and the use of a dynamic biomarker (circulating tumor DNA clearance) as an early surrogate correlate of treatment response. The domain spans diagnostic radiology/urologic oncology, clinical pharmacology, and molecular oncology, unified by the broader discipline of evidence-based clinical medicine.
This content is a clinical-research news roundup rather than a unified theoretical lecture. Its core underlying principle is diagnostic test evaluation theory: a screening or imaging modality's clini…